AKER News and Press, Akers Biosciences Inc. From 11/22/19

THOROFARE, N.J., Nov. 22, 2019 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ: AKER), (“Akers Bio” or the "Company"), a developer of rapid health information technologies, today announced that effective at 8:00 a.m. eastern standard time on Monday, November 25, 2019, the ...

Akers Biosciences (NASDAQ: AKER ) has filed a preliminary prospectus for a public offering of Class A & B Units valued up to $7.5M. More news on: Akers Biosciences, Inc., Healthcare stocks news, Read more ...

2019 has been a pretty rough year in the market with benefactors such as tweetstorms from Trump, decreasing global industrial production and manufacturing numbers, and escalating conflicts between the west and the east. Economists believe that 2020 will be the most volatile year in the stock m...

Akers Biosciences (NASDAQ: AKER ): Q2 GAAP EPS of -$0.06. More news on: Akers Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Continued Progress Toward Positioning the Company for Strategic Alternatives THOROFARE, N.J., Aug. 15, 2019 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ: AKER) (“Akers Bio” or the “Company”), a developer of rapid health information technologies, report...

Akers Biosciences (NASDAQ: AKER ): Q1 operating loss of $0.90M. Cash, restricted cash and marketable securities of $5.23M Press Release More news on: Akers Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, ,

Continued Progress Toward Positioning the Company for Strategic Alternatives THOROFARE, N.J., May 20, 2019 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ: AKER) (“Akers Bio” or the “Company”), a developer of rapid health information technologies, reporte...

Ongoing Measures to Streamline Operations, Reduce Costs and Position the Company for Strategic Alternatives THOROFARE, N.J., April 01, 2019 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ: AKER) (“Akers Bio” or the “Company”), a developer of rapi...